SCHEMBL1277922

SCHEMBL1277922

C/C(=C\c1ccc(C)cc1-c1ccc(C(=N)N)c(F)c1)C(=O)NC(=N)N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.36
F2 P00734 3/20 0.36
PLG P00747 2/20 0.36
PLAU P00749 2/20 0.36
PLAT P00750 2/20 0.36
SLC9A3 P48764 2/20 0.36
SLC9A1 P19634 2/20 0.36
KLK1 P06870 2/20 0.33
KLK5 Q9Y337 2/20 0.33
ACVR1 Q04771 1/20 0.32
KLKB1 P03952 2/20 0.31
ROCK2 O75116 1/20 0.31
MAP4K4 O95819 1/20 0.31
LCK P06239 1/20 0.31
CDK1 P06493 1/20 0.31
FLT1 P17948 1/20 0.31
AXL P30530 1/20 0.31
FLT4 P35916 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277605 0.88 SLC9A3 (0.36) F10F2PLGPLAUPLAT
SCHEMBL1277169 0.87 F10 (0.40) F10F2PLGPLAUPLAT
SCHEMBL1277503 0.86 AR (0.40) F10SLC9A3SLC9A1ROCK2MAP4K4
SCHEMBL1277355 0.84 SLC9A3 (0.39) F10F2PLGPLAUPLAT
SCHEMBL1277438 0.82 SLC9A3 (0.40) F10SLC9A3SLC9A1GRM2
SCHEMBL1277251 0.80 SLC9A3 (0.38) SLC9A3SLC9A1
SCHEMBL1277172 0.78 SLC9A3 (0.35) SLC9A3SLC9A1KDR
SCHEMBL1277372 0.78 FYN (0.40) SLC9A3SLC9A1
SCHEMBL1277298 0.78 AR (0.42) F10F2PRSS1DHODH
SCHEMBL1277373 0.75 F10 (0.39) F10F2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885F2 4881/4885PLG 4845/4885
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885F2 4881/4885PLG 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.